When it comes to a sport as lucrative as bodybuilding, it is not a surprise when one hears about ongoing relationship between sex, drugs, and bodybuilding.
One can find many incidents in the past that clearly suggested that this relationship has continued to nurture despite all odds and criticism from the stalwarts. What is amusing to note is the fact that this relationship has not reduced but gained over a couple of years.
From SteroidTimes.Com:
Testosterone is likely to be the most commonly used, well recognized drug that earns an “A+” in both athletics and sexual performance. It’s muscle building and athletic enhancing properties are undeniable and have been commonplace in sports and Hormone Replacement Therapy clinics for decades. Testosterone is directly responsible for increases in libido and penile erection frequency and easily earns a reputation as the Gold Standard for anyone wanting to thoroughly maximize their potential.
Next on our list are prescription vasodialators such as Viagara, Cialis and Levitra. Just as the name implies, these drugs cause the arterial blood vessels to dilate and increase blood flow in the body, particularly in tissues with higher metabolic needs, such as working muscles during a workout. The decrease in blood pressure caused by this group of drugs also helps to maximize cardiovascular output. During a workout, the user can expect to have a better “pump” causing more blood, oxygen, and nutrients to flow to working muscles and in return, allowing the muscles to work harder and recover faster. In the bedroom, vasodialators cause increased blood flow to the penis, which, as the commercials warn, could go so far as to require you to “call your doctor if you experience an erection lasting more than 4 hours”. I doubt anyone will argue that prescription vasodialators earn an “A-” in the bedroom and a “C” in the gym or on the field.
With demands for drugs and bodybuilding, sex was not too far to join them. After all, all three of them are related to one another, in one way or the other.
